Details:
Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and related compounds.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Allergan Aesthetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 13, 2022
Details:
Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorporating the ingredient.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: RODAN & FIELDS LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 16, 2022
Details:
Study conducted by Dr. Zoe Draelos has been peer reviewed & accepted for publication in the Journal of Cosmetic Dermatology. TFC-1067 demonstrated the ability to lighten dark spots to blend into surrounding skin while preserving overall complexion.
Lead Product(s): TFC-1067
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. TFC-1067 has been clinically proven to selectively lighten dark spots and blend them into surrounding skin tone.
Lead Product(s): TFC-1067
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2020
Details:
Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The cannabis research license by Health Canada allows the Crescita to possess cannabis for the purpose of research and development.
Lead Product(s): Cannabinoid-based Product
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020
Details:
TFC-1067 demonstrated very good skin compatibility and does not show a sensitizing effect.
Lead Product(s): TFC-1067
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020